18 November 2017
News and Views
Links and Services
A recent study in the Alimentary Pharmacology & Therapeutics investigates the impact of infliximab therapy influences clinical response to certolizumab pegol maintenance therapy for Crohn's disease.
Certolizumab pegol is an effective therapy for Crohn's disease refractory to aminosalicylates, co
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors